Clinical trial · Observational
Relationship Between Periodontal Disease and Postmenopausal Osteoporosis
Investigation of the Relationship Between Periodontal Disease and Serum and Gingival Crevicular Fluid Sclerostin and Tumor Necrosis Factor- α Levels in Women With Postmenopausal Osteoporosis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Elevated sclerostin levels in serum and alveolar bone of osteoporotic patients may exert deleterious effects on the periodontium, thereby contributing to the progression and increased severity of periodontal disease. Moreover, sclerostin is considered a potential biomarker for elucidating the shared pathophysiological mechanisms linking postmenopausal osteoporosis and periodontitis
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Periodontal Disease | — | UNRESOLVED | — |
| Postmenopausal Osteoporosis (PMO) | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| clinical assessment | Other | — | UNRESOLVED |
| Radiographic Evaluation | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Group C (Control)
- description
- Periodontally and systemically healthy women without osteoporosis (n=20)
- interventionNames
- Other: clinical assessment
- Diagnostic Test: Radiographic Evaluation
- label
- Group P (Experimental)
- description
- Women with periodontitis and without osteoporosis (n=20)
- interventionNames
- Other: clinical assessment
- Diagnostic Test: Radiographic Evaluation
- label
- Group O (Experimental)
- description
- Periodontally healthy women with osteoporosis (n = 20)
- interventionNames
- Other: clinical assessment
- Diagnostic Test: Radiographic Evaluation
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 43 Years
- Maximum age
- 78 Years
Show eligibility criteria text
Inclusion Criteria: * Female patients aged 40 years and older in the postmenopausal period, * Individuals diagnosed with osteoporosis or healthy individuals without osteoporosis, as determined by DXA testing of the hip or spine, * Individuals who had been postmenopausal for ≥6 months and had not received hormone replacement therapy, * Patients who did not smoke or consume alcohol, * Female patients who were periodontally healthy or diagnosed with Stage 2-3, Grade A periodontitis Exclusion Criteria: * Patients with chronic renal and hepatic insufficiency; malignant diseases such as diabetes mellitus, leukemia, multiple myeloma, and widespread carcinoma; chronic inflammatory rheumatic diseases such as rheumatoid arthritis and ankylosing spondylitis; and those using drugs that may affect bone metabolism (glucocorticoids, heparin, methotrexate, anticonvulsants), * Those who had received antibiotic therapy in the previous 3 months or any medication for osteoporosis treatment, * Patients who had undergone surgical or non-surgical periodontal treatment within the previous 6 months, * Patients who did not wish to continue participation in the study at the midpoint or at the end of the study.
References
Publications (0)
Data not yet available